Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

CHADDS FORD, Pa., April 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter of 2009, including results beginning on February 23, 2009 for Indevus Pharmaceuticals, which Endo acquired during the quarter.

Net sales during the first quarter of 2009 increased 16% to $335.3 million compared with $290.3 million in the first quarter of 2008. Net income for the three months ended March 31, 2009 was $39.0 million compared with $59.5 million in the comparable 2008 period. As detailed in the Supplemental Financial Information below, adjusted net income for the three months ended March 31, 2009 was $79.0 million compared with $68.2 million in the same period in 2008.

Diluted earnings per share for the three months ended March 31, 2009 were $0.33 compared with $0.44 in the first quarter of 2008. Adjusted diluted earnings per share for the three months ended March 31, 2009 were $0.67 compared with $0.51 in the same period in 2008.

"We had a solid first quarter during which we diversified our commercial business beyond pain management, reorganized our sales and marketing and R&D groups, and repositioned our company for sustainable future growth," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "I believe our broader therapeutic focus on urology and oncology and more capable specialty infrastructure will enable us to meet aggressive long-term growth targets and adapt quickly to a changing healthcare environment."

Selected Product Review

PAIN PRODUCTS

LIDODERM(R): For the quarter ended March 31, 2009, net sales of LIDODERM decreased 5% to $171.6 million compared with $180.5 million in the same period a year ago. Prescription volume for LIDODERM decreased 2% in the first quarter of 2009 versus the comparable 2008 period.

OPANA(R) ER and OPANA(R): Combined net sales for the OPANA franchise increased 31% to $52.8 million for the first quarter 2009 compared with $40.3 million in the same period a year ago. Prescription volume for OPANA ER and OPANA increased 58% in the first quarter 2009 versus the comparable 2008 period.

FROVA(R): Net sales of FROVA were $12.3 million for the three months ended March 31, 2009 compared with $14.1 million for the same period in 2008.

Voltaren(R) Gel: Net sales of Voltaren Gel were $12.3 million for the three months ended March 31, 2009. Voltaren Gel was launched in March 2008. Responding to marketplace demand, Voltaren Gel 3 & 5 Packs became available in April 2009.

ONCOLOGY/ENDOCRINOLOGY PRODUCTS

For the first quarter of 2009, net sales of other branded products were $10.2 million compared with $1.8 million in the same period in 2008. Included in other branded products are net sales from products recently obtained through our acquisition of Indevus Pharmaceuticals, Inc. for the period February 23, 2009 through March 31, 2009. Net Sales of SUPPRELIN(R) LA applicable to Endo results for the first quarter were $2.7 million. Net Sales of VANTAS(R) applicable to Endo results for the first quarter were $1.9 million.

GENERIC AND NON-PROMOTED PRODUCTS

For the first quarter of 2009, net sales from the company's generic products were $42.4 million compared with $21.8 million in the same period in 2008. Net sales of Percocet(R) were $33.7 million for the three months ended March 31, 2009 compared with $31.8 million in the same period in 2008. During the first quarter of 2009, the company benefited from a market shortfall in the supply for certain generic products.

Acquisition of Indevus Pharmaceuticals, Inc.

During the first quarter of 2009, we completed our acquisition of Indevus Pharmaceuticals, Inc. and acquired 100% of the outstanding shares of Indevus for a purchase price of $4.50 per share in cash and the non-transferable contractual right to receive up to an additional $3.00 per share in cash payable in the future upon achievement of certain regulatory and sales milestones. The results of operations for Indevus have been included in our consolidated operating results beginning on February 23, 2009.

Conference Call Information

Endo will conduct a conference call with financial analysts to discuss this news release today at 10:30 a.m. ET. Investors and other interested parties may call 866-383-7998 (domestic) or 617-597-5329 (international) and enter code 54725288. Please dial in 10 minutes prior to the scheduled start time.

A replay of the call will be available from April 29 at 1:30 p.m. ET until 12:00 a.m. ET on May 6 by dialing 888-286-8010 (domestic) or 617-801-6888 (international), pass code 95260431. A simultaneous webcast of the call may be accessed by visiting www.endo.com. In addition, a replay of the webcast will be available until 12:00 a.m. ET on May 6. The replay can be accessed by clicking on "Events" in the Investor Relations section of the website.

Supplemental Financial Information

The following tables provide a reconciliation of our GAAP statements of operations to our adjusted statements of operations for each of the three months ended March 31, 2009 and March 31, 2008 (Certain prior period amounts have been reclassified to conform to the current period presentation) (in thousands, except per share data):


    Three Months Ended March 31,      Actual
     2009 (unaudited)                 (GAAP)     Adjustments      Adjusted

    Net sales                        $335,300          $-          $335,300
    Costs and expenses:
      Cost of sales                    83,009     (12,996) (1)       70,013
      Selling, general and
       administrative                 120,006           -           120,006
      Research and development         28,414      (9,438) (2)       18,976
      Acquisition-related costs        26,405     (26,405) (3)            -

    Operating income                   77,466      48,839           126,305

      Interest expense, net             7,593      (3,781) (4)        3,812
      Other expense, net                1,105         172  (5)        1,277

    Income before income taxes         68,768      52,448           121,216
      Income taxes                     29,731      12,462  (6)       42,193

    Net income                        $39,037     $39,986           $79,023

    Diluted earnings per share          $0.33                         $0.67
    Diluted weighted average
     shares                           117,209                       117,209


    Notes to reconciliation of our GAAP statements of operations to our
    adjusted statements of operations:

    (1) To exclude amortization of commercial intangible assets related to
        marketed products ($11,377) and the impact of the Indevus inventory
        step-up recorded as part of acquisition accounting ($1,619).
    (2) To exclude upfront and milestone payments to partners.
    (3) To exclude Indevus transaction and separation costs.
    (4) To exclude additional interest expense as a result of adopting APB
        14-1
    (5) To exclude changes in fair value of financial instruments, net.
    (6) To reflect the tax effect of the pre-tax adjustments above at the
        applicable tax rates and the cash tax savings resulting from the
        Indevus acquisition.


    Three Months Ended March 31,      Actual
     2008 (unaudited)                 (GAAP)      Adjustments   Adjusted

    Net sales                        $290,271           $-      $290,271
    Costs and expenses:
      Cost of sales                    56,534       (4,189) (1)   52,345
      Selling, general and
       administrative                 115,002       (3,278) (2)  111,724
      Research and development         33,582       (6,450) (3)   27,132

    Operating income                   85,153       13,917        99,070

      Interest income, net             (9,265)           -        (9,265)
      Other expense, net                  282            -           282

    Income before income taxes         94,136       13,917       108,053
      Income taxes                     34,608        5,239  (4)   39,847

    Net income                        $59,528       $8,678       $68,206

    Diluted earnings per share          $0.44                      $0.51
    Diluted weighted average
     shares                           134,652                    134,652


    Notes to reconciliation of our GAAP statements of operations to our
    adjusted statements of operations:

    (1) To exclude amortization of commercial intangible assets related to
        marketed products.
    (2) To exclude separation costs.
    (3) To exclude upfront and milestone payments to partners.
    (4) To reflect the tax effect of the pre-tax adjustments above at the
        applicable tax rates.

For an explanation of Endo's reasons for using non-GAAP measures, see Endo's Current Report on Form 8-K filed today with the Securities and Exchange Commission.


         Reconciliation of Projected GAAP Diluted Earnings Per Share to
                 Adjusted Diluted Earnings Per Share Guidance

                                                         Year Ended
                                                      December 31, 2009

    Projected GAAP diluted income per common
     share                                         $1.73      to     $1.81
    Upfront and milestone payments to
     partners                                      $0.26             $0.26
    Amortization of commercial intangible
     assets                                        $0.48             $0.48
    Indevus transaction and separation costs       $0.23             $0.23
    Interest expense adjustment for APB 14-1       $0.12             $0.12
    Tax effect of pre-tax adjustments at the
     applicable tax rates and certain other
     expected cash tax savings as a result
     of the Indevus acquisition                   ($0.23)           ($0.23)
    Diluted adjusted income per common share
     guidance                                      $2.59      to     $2.67



    The company's guidance is being issued based on certain assumptions
    including:
        -- Adjusted effective tax rate of approximately 34% in 2009;
        -- Weighted average number of common shares outstanding of 117
           million shares for the year ended December 31, 2009;
        -- The February 23, 2009 acquisition date of Indevus
           Pharmaceuticals, Inc.; and
        -- Certain of the above amounts are based on preliminary estimates
           and there can be no assurance that Endo will achieve these
           results.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM(R), a topical patch to relieve the pain of postherpetic neuralgia; Percocet(R) and Percodan(R) tablets for the relief of moderate-to-moderately severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA(R) tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA(R) ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R)Gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees. Voltaren(R)Gel is owned and licensed by Novartis AG; SANCTURA(R) and its XR version for treatment of overactive bladder, VANTAS(R) for the palliative treatment of advanced prostate cancer, and SUPPRELIN(R) LA for the treatment of early onset puberty in children. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the acquisition of Indevus, the company's financial position, results of operations, market position, product development and business strategy, as well as estimates of future net sales, future expenses, future net income and future earnings per share. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to; the possibility that the acquisition of Indevus is not complementary to Endo; the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; competition in our industry, including for branded and generic products, and in connection with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release and on the related conference call are qualified by these risk factors. These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected and historical results. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

(Tables Attached)

The following tables present Endo's unaudited net sales for the three months ended March 31, 2009 and March 31, 2008:

                            Endo Pharmaceuticals Holdings Inc.
                                 Net Sales (unaudited)
                                    (in thousands)


                                                    Three Months Ended
                                                         March 31,

                                                    2009             2008

    LIDODERM(R)                                  $171,636         $180,524
    OPANA(R) ER AND OPANA(R)                       52,765           40,283
    Percocet(R)                                    33,690           31,800
    FROVA(R)                                       12,292           14,055
    Voltaren(R) Gel                                12,319                -
    Other Brands *                                 10,205            1,816

    Total Brands                                 $292,907         $268,478

    Total Generics                                $42,393          $21,793

        Total Net Sales                          $335,300         $290,271


    *Other Brands includes Indevus results beginning on February 23, 2009.

The following table presents condensed consolidated cash flow data for the three months ended March 31, 2009 and March 31, 2008:

                         Endo Pharmaceuticals Holdings Inc.
                    Condensed Consolidated Cash Flow Data (unaudited)
                                   (in thousands)


                                                     Three Months Ended
                                                           March 31,

                                                       2009         2008

    Net cash provided by operating activities        $35,031      $75,453

    Net cash (used in) provided by investing
     activities                                     (423,555)     125,385

    Net cash provided by (used in) financing
     activities                                        6,988         (623)

    Net (decrease) increase in cash and cash
     equivalents                                   $(381,536)    $200,215

    Cash and cash equivalents, beginning of
     period                                         $775,693     $350,325

    Cash and cash equivalents, end of period        $394,157     $550,540




'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
(Date:2/5/2016)... ... 2016 , ... Regular gym users know the routine: each January, they see ... the treadmills. It’s a predictable trend. After the excesses of November and December, people ... by joining gyms, starting new walking or running routines, or signing up for Zumba. ...
(Date:2/5/2016)... ... 2016 , ... At its annual meeting held last week, the American Parkinson ... Board of Directors. Mr. McDermott succeeds former APDA Chairman, Fred Greene. , "We are ... , APDA President and CEO. “Pat has tirelessly served APDA since 2001 when he ...
(Date:2/5/2016)... ... February 05, 2016 , ... Colorize is a web theme ... to the next using Colorize's dynamic moving camera. Colorize is perfect for personal and ... 3D slideshow environment with 1 to 5 focus points per scene, stage floor scene ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016  Aralez Pharmaceuticals Inc. ("Aralez") today announced the ... Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the ... The combined company will operate under Aralez Pharmaceuticals Inc. ... Canada , Ireland ... Under the terms of the Agreement and Plan of ...
(Date:2/5/2016)... , Feb. 5, 2016  Venice,s newest laser ... the first of its kind in the area ... through advanced laser treatment. The physician-owned and operated ... Suncoast by storm with its revitalizing skin ... advanced multi-wavelength Astanza Trinity technology. http://photos.prnewswire.com/prnh/20160204/329957 ...
(Date:2/5/2016)... Ind. , Feb. 5, 2016  Zimmer Biomet ... pricing of the previously announced underwritten secondary offering of ... its stockholders, consisting of affiliates of Blackstone and Goldman ... at an initial price of $96.45 per share. The ... the offering.  Neither Zimmer Biomet nor any of its ...
Breaking Medicine Technology: